Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|May 20, 2026

The BioPharm Brief: RNA Editing, Liver Safety, Joint Gains

New clinical trial updates highlight advances in RNA editing for alpha-1 antitrypsin deficiency, semaglutide data in MASH liver disease, and improved joint outcomes in psoriatic arthritis treatment comparisons.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today’s update focuses on three clinical stories drawing attention across the biotech and pharmaceutical landscape: promising RNA editing data in alpha-1 antitrypsin deficiency, new semaglutide findings in liver disease, and competitive trial results in psoriatic arthritis.

First, Wave Life Sciences reported early clinical data for WVE-006, an investigational RNA editing therapy targeting alpha-1 antitrypsin deficiency. In the Phase 1b/2a study, researchers said the therapy achieved protein levels associated with the milder “MZ-like” phenotype, potentially reducing disease severity. The approach uses RNA editing rather than permanent DNA modification, a strategy that continues to gain attention as developers look for more targeted genetic medicines.

Next, Novo Nordisk presented additional analyses on semaglutide in metabolic dysfunction-associated steatohepatitis, or MASH, during EASL 2026. The company highlighted liver safety findings and subgroup analyses from the ESSENCE program, including data involving postmenopausal women and Japanese patient populations. The results add to growing evidence supporting GLP-1 therapies in liver disease management, an area receiving increasing industry focus as MASH diagnoses continue to rise globally.

And finally, UCB announced new BE BOLD trial data showing Bimzelx, or bimekizumab, demonstrated stronger joint-related outcomes than risankizumab in adults with active psoriatic arthritis. Nearly half of patients receiving bimekizumab achieved the stringent ACR50 endpoint at Week 16, compared with just over 38 percent in the comparator arm. Researchers also noted earlier improvements in joint symptoms and no unexpected safety concerns.


Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • RNA editing therapy WVE-006 showed encouraging early clinical results in alpha-1 antitrypsin deficiency.
  • Novo Nordisk expanded semaglutide data supporting liver safety and subgroup effectiveness in MASH patients.
  • Bimzelx outperformed risankizumab on key joint outcomes in the BE BOLD psoriatic arthritis study.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more